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Introduction 
 
Metabolic syndrome (MetS) or insulin resistance 
syndrome is defined as a cluster of cardiometa-
bolic risk factors including of the following char-
acteristics: abdominal adiposity, dyslipidemia, 
Abstract 
Background: Metabolic syndrome (MetS), a cluster of cardiometabolic risk factors, consider as a manifestation 
of obesity. However, a proportion of obese patients do not develop MetS. The aim of our study was to deter-
mine whether concentration of plasma adiponectin and leptin differ between metabolic unhealthy obese 
(MUO) patients and comparable age- and sex-matched control groups. 
Methods: In this case-control study, we assigned 51 obese patients with MetS (MUO) in cases group and 102 
metabolic healthy obese (MHO) and normal weight metabolic healthy subjects matched for age and gender to 
cases in control groups. The study was conducted between December 2014 and February 2016 in the Endocri-
nology Research Center of Tehran University of Medical Sciences , Tehran , Iran.  We measured serum adi-
ponectin, leptin, their ratio, and body composition in all subjects. 
Results: No significant differences were observed between MHO and MUO in term of total fat mass and 
trunk fat (P>0.05). Compared to MHO and normal weight metabolic healthy subjects, MUO subjects had low-
er levels of plasma adiponectin (P<0.001) and lower plasma adiponectin to leptin ratio (P<0.001) and a higher 
level of plasma leptin (P<0.002). A Receiver Operator Characteristic curve was used to identify the ability of 
adiponectin and leptin level to predict the MetS. The area under the Receiver Operator Characteristic curve was 
0.66 (P<0.01), 0.73 (P<0.001) and 0.75 (P<0.001) for leptin, adiponectin, and adiponectin/leptin ratio levels 
respectively. 
Conclusion: Our study introduced adiponectin and leptin as indicator of MetS and obesity respectively. 
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high blood pressure, fasting glucose, or insulin 
resistance (1). MetS is one of the leading global 
public health issues (2). The number of patients 
with MetS in developed and developing countries 
is expanding (3, 4). Its prevalence varies between 
15% and 40% (5), with a higher rate in develop-
ing countries (5). MetS poses an increased risk of 
coronary heart disease (CHD), type 2 diabetes 
mellitus (DM2), and other cardiometabolic dis-
eases (6). 
In spite of various pathogenic mechanisms pro-
posed, the etiology and concept of the MetS still 
remains obscure and controversial and is under 
intense investigation (7). Although the prevalence 
of MetS increases with obesity, MetS can be pre-
sent in lean individuals; furthermore, a propor-
tion of obese patients do not affected by MetS so 
called “healthy obese phenomenon” (8). Recent 
research introduced adipocytes-derived hor-
mones, as mediators linking adipocytes-
dysfunction to MetS (9, 10). These so-called adi-
pokines are important determinants of insulin 
resistance and obesity (11). Adiponectin and lep-
tin are two most widely studied adipocytokines in 
relation to MetS (9, 10). 
Adiponectin, the most abundant anti-atherogenic 
and anti-inflammatory adipocytokine found in 
circulation has direct effects on glucose and lipid 
metabolism, improves insulin sensitivity and cen-
tral fat distribution (12, 13). Adiponectin levels 
are inversely correlated with visceral adiposity 
(14). A lower level of adiponectin is associated 
with insulin resistance, obesity, MetS and CVD 
(15, 16). Low level of circulating adiponectin may 
be used as a possible biomarker for MetS (17). 
On the other hand, Leptin as an anti-obesity adi-
pocytokine plays critical roles in regulating food 
intake, maintaining energy expenditure and body 
weight (15). Serum leptin levels in patients with 
MetS are higher than those in healthy controls 
(18). Increased leptin level predicts metabolic 
syndrome development independent of obesity 
(19). In fact, adiponectin and leptin levels show 
an inverse correlation with each other (19). 
Therefore, to be integrated their critical roles in 
MetS, adiponectin/leptin ratio has been identified 
to be useful serum markers for diagnosis of MetS 
(20, 21), and even to predict of CV outcome (22). 
The aim of this study was to determine adiponec-
tin and leptin profiles and their ratio from serum 
in MUO patients compared to age and gender-
matched control groups. 
 
Materials and Methods 
 
Subjects 
The study was a case-control study comprising 51 
metabolically unhealthy obese (MUO) as cases 
and 102 metabolically healthy obese (MHO) and 
normal weight metabolic healthy as control 
groups (51 subjects in each group). The study 
was conducted between December 2014 and 
February 2016 in Tehran the Endocrinology Cen-
ter of Tehran University of Medical Sciences, 
Tehran, Iran. Fifty-one patients newly diagnosed 
with MetS and never receiving medications were 
included in this study as MUO group. The two 
control groups included 51 MHO and 51 normal 
weight metabolic healthy subjects (healthy). Sub-
jects were matched for age and gender. The sam-
ple size was calculated based on previous study 
with the minimum differences in waist to hip ra-
tio by 0.05 and standard deviation by 0.14, with 
the power of 80% and α error of 5%, we deter-
mine the sample size of 50 in every case and con-
trol groups. 
Informed consent was obtained from all the sub-
jects participating in the study. The research pro-
tocol of the study was approved by Scientific Re-
search Committee of Iran University of medical 
science (93-02-27-24976). 
 
Diagnostic criteria for the metabolic syn-
drome 
Diagnostic criteria recommended National Cho-
lesterol Education Program (NCEP) - Adult 
Treatment Panel (ATP III) (NCEP ATPIII) was 
used to define MetS. 
Waist circumference (WC) was measured be-
tween the lower rib margin and the iliac crest by a 
flexible tape measure after normal expiration. 
Body weight was measured while participants 
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wore light clothing using calibrate scale to an ac-
curacy of ±0.5 kg (23, 24). Standing height was 
measured with a standard stadiometer to the 
nearest 0.1 cm, measuring the participants with-
out shoes, erect and with the back against a flat 
surface (24). Systolic and diastolic blood pressure 
was measured on the non-dominant brachial ar-
tery in the sitting position after the subject resting 
for at least 10 min by a specialist nurse (23, 24). 
Blood pressure was measured twice separately 
over a 3-min interval. The average blood pressure 
considered as blood pressure value. Levels of 
TG, HDL-c, and FBS were evaluated from pa-
tients medical chart records.  
 
Exclusion and inclusion criteria 
Having a history of coronary artery disease, acute or 
chronic renal failure, acute infection within the pre-
vious seven days, acute or chronic hepatic failure, 
hematological disorder, presence of any chronic 
inflammatory and autoimmune disease, and any 
known malignancy, hormone therapy, taking phy-
toestrogens or drug intended to decrease lipid level. 
Other non-pathological exclusion criteria included 
pregnancy, breastfeeding, post-menopause, smok-
ing, professional athlete, uncontrolled thyroid dis-
order, use of medications for dyslipidemia or hyper-
tension, hypnotics, sedatives and immunosuppres-
sive or having a special diet for any reason pre-
scribed by the clinic dietitian. 
The inclusion criteria included age range 20-55 yr 
and provided written consent of participation. 
 
Assay for leptin and adiponectin 
Peripheral venous blood sample was drawn after 
more than 8 h of fasting overnight. Serum adipo-
cytokine levels (leptin and adiponectin) were 
measurements by enzyme-linked immune-
sorbent assay (ELISA) using a Mediagnost Kit 
(Reutlingen/Germany). The assay was conducted 
according to the manufactures instructions. 
Plasma samples required 310-fole dilution for 
adiponectin. 
 
Body composition measurement 
Body composition component including were 
measured using 8-contact electrode method of 
Bio-Electrical Impedance Analysis (BIA) (model 
TANITA BC-418). For this purpose, the subjects 
were asked to empty their bladder prior to the 
testing and stand on metal footpads in bare feet 
and grasp a pair of electrodes fixed on a handle. 
There is a significant correlation regarding the 
data obtained from BIA and DXA (25). 
 
Statistical analysis 
SPSS 16.0 software was used for basic statistical 
analysis (SPSS Inc., Chicago, IL, USA). Compari-
sons between three groups were carried out using 
the one-way ANOVA. When the result of the 
ANOVA test was significant, a LSD test was 
used to locate which of the means differed. 
Moreover, the analysis of covariance (ANCOVA) 
was used for adjustment on fat components in 
assessing the association between adiponectin 
and leptin level among the study groups. Receiver 
Operator Characteristic curve (ROC curves) was 
used for determining the appropriate cut off 
point and its sensitivity and specificity of adi-
ponectin, leptin levels and also adiponec-
tin/leptin ratio for predicting metabolic syn-
drome. Multiple linear regression analysis was 
used to assess the association between adiponec-
tin and other study parameters. In addition, it was 
applied to identify whether leptin, adiponectin 
and its ratio were independently associated with 
MetS. A value of P<0.05 was accepted as statisti-
cally significant. 
 
Results 
 
The characteristics and MetS components of our 
subjects with respect to study groups are summa-
rized in Table 1. 
In one way analysis of variance (one way-
ANOVA), leptin was significantly different be-
tween obese subjects with/without Mets groups 
(MHO and MUO groups) and normal weight 
metabolic healthy subjects. MUO patients had 
higher levels of leptin (14.06±12.4) compared to 
those without MetS (11.2±9.3 Vs 7.09±7.1 in 
MHO and normal weight metabolic healthy re-
spectively; P=0.002) (Table 1). Moreover, in anal-
ysis of covariance (ANCOVA), after adjustment 
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for fat content, there is still a significant associa-
tion between leptin and study groups (P=0.015), 
so that the mean of leptin in MUO patients was 
significantly lower compared to average concen-
trations in the normal weight metabolic healthy 
group (Tables 2,3).  
  
Table 1: General characteristics, MetS parameters AND serum adiponectin, leptin and adiponectin/leptin ratio of 
subjects based on study groups 
 
Variable MUO(51) MHO(51) Normal weight 
metabolic healthy 
(n=51) 
Total (153) 
 
P-value* 
 mean±SD mean±SD mean±SD mean±SD  
Age (year) 37.47±6.5 36.94±6.4 35.93±6.3 36.78±6.4 0.47 
Weight (Kg) a92.5±13.3 a89.1±13.7 b69.1±6.8 83.6±15.58 <0.0001 
Height (Cm) 171.49±7.7 172.2±7.03 171.1±6.8 171.6±7.1 0.74 
WC (Cm) a105.09±8.1 b100.2±11.3 c87.02±7 97.4±11.79 <0.0001 
BMI (Kg/m2) a31.43±3.7 b29.9±3.6 c23.6±1.4 28.3±4.5 <0.0001 
SBP (mm-Hg) a121.2±11.7 b113.8±8.6 b111.3±12.2 115.4±11.6 <0.0001 
DBP (mm-Hg) a80.8±9.1 b75.7±6.6 b74.1±8.3 76.8±8.5 <0.0001 
FBS (mg/dl) a116.2±37.3 b97.8±20.4 b95.2±7.6 103.1±26.4 <0.0001 
TG (mg/l) a266.3±203.6 b131.05±87.4 b117.5±67.8 171.6±149.02 <0.0001 
HDL-c (mg/dl) a50.3±8.3 b54.3±5.6 b55.09±9.2 53.2±8.09 0.006 
MetS parameters a3.31±0.61 b1.05±0.75 b0.8±0.63 1.7±1.3 <0.0001 
Leptin(ng/ml) a14.06±12.4 a11.2±9.3 b7.09±7.1 10.8±10.2 0.002 
Adiponectin(µg/ml) a4.85±1.8 b6.7±2.8 b7.25±3.2 6.25±2.8 <0.0001 
Adiponectin/leptin a0.58±0.56 b1.17±1.3 c2.01±2.1 1.24±1.6 <0.0001 
Values are analyzed by one–way ANOVA, values are mean ± SD. 
Dissimilar values (a, b, c) of each row are significantly different  
 
Table 2: Analysis of covariance for assessing association between adiponectin and leptin with study groups 
 
Variable Source Sum of squares df Mean square F P-value 
Adiponectin (µg/ml) Intercept 212.63 1 212.63 31.00 <0.001 
Fat mass 24.50 1 24.50 3.57 0.061 
Study groups 184.39 2 92.19 13.44 <0.001 
Error 1008.20 147 6.85   
Total 7094.24 151    
Leptin (ng/ml) Intercept 3382.31 1 3382.31 90.43 <0.001 
Fat mass 8949.26 1 8949.26 239.28 <0.001 
Study groups 325.48 2 162.74 4.35 0.015 
Error 5497.85 147 37.40   
Total 33446.96 151    
Adiponectin/leptin Intercept 128.63 1 128.63 71.72 <0.001 
 Fat mass 59.41 1 59.41 33.12 <0.001 
 Study groups 9.85 2 4.92 2.74 0.067 
 Error 263.63 147 1.79   
 Total 608.73 151    
 
The serum adiponectin level was significantly dif-
ferent between MUO and non-MetS groups 
(MHO and normal weight metabolic healthy 
groups). MUO patients (4.85±1.8) had signifi-
cantly (P<0.0001) lower adiponectin level com-
pared to MHO group (6.7±2.8) and normal 
weight metabolic healthy group (7.25±3.2) (Table 
1). In analysis of covariance (ANCOVA), after 
adjustment for fat content, there was still a signif-
icant association between adiponectin and study 
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groups (P<0.001), so that the mean of adiponec-
tin in MUO patients was significantly lower com-
pared to average concentrations in the MHO and 
normal weight metabolic healthy groups (Tables 
2, 3). Adiponectin/leptin ratio was 0.58±0.56 in 
the MUO group and 1.17±1.3 in MHO and 
2.01±2.1 in normal weight metabolic healthy 
groups (P<0.0001) (Table 2). However, in analy-
sis of covariance (ANCOVA) after adjustment 
for fat content, the mean of Adiponectin/leptin 
ratio in MUO patients was lower than the aver-
age concentrations in the MHO and normal 
weight metabolic healthy groups, but this associa-
tion was not statistically significant (P=0.067) 
(Tables 2,3).  
A Receiver Operator Characteristic curve was 
used to identify the ability of leptin, adiponectin 
and their ratio levels to predict the MetS (Table 4).  
 
Table 3: Estimated marginal means of adiponectin and leptin among case and control groups 
 
Variable MUO(51) MHO(51) Normal weight 
metabolic healthy 
(n=51) 
P-value* 
 mean±SD mean±SD mean±SD  
Leptin(ng/ml) 10.51±6.28a 9.07±6.14a 13.01±6.78b 0.015 
Adiponectin(µg/ml) 4.66±2.71a 6.57±2.64b 7.56±2.85b <0.001 
Adiponectin/leptin 0.87±1.35a 1.34±1.35 a 1.53±1.42b 0.067 
Values are analyzed by analysis of covariance (ANCOVA), values are mean ± SD. 
Dissimilar values (a, b, c) of each row are significantly different 
 
Table 4: Area under the ROC curve, sensitivity, specificity and cutoff value for leptin, adiponectin and adiponec-
tin/leptin as predictor MetS 
 
Variable AUC (95% CI) Sensitivity Specificity P-value 
Leptin (8.1) 0.66 (0.57-0.75) 67.0% 64.0% <0.001 
Adiponectin (5.75) 0.73 (0.65-0.81) 73.0% 61.0% <0.0001 
Adiponectin/leptin 
(0.726) 
0.75 (0.67-0.83) 75.0% 61.0% <0.0001 
AUC: area under the curve; CI: confidence interval 
 
ROC curves and area under the curve (AUC) for 
the ability of adiponectin/leptin ratio to predict 
MetS are shown in Fig. 1. The cutoff for leptin, 
adiponectin and their ratio were 8.1 (ng/ml), 5.75 
(µg/ml) and 0.726, respectively. The area under 
the Receiver Operator Characteristic curve was 
0.66, 0.73 and 0.75 for leptin, adiponectin and 
their ratio levels, respectively (P>0.05). 
Linear regression analysis was used to assess as-
sociation between adiponectin and other study 
parameters (Table 5). In linear regression analysis 
with crude model (model 1), there was a signifi-
cant association between adiponectin and gender 
(P=0.001), study groups (P<0.001), weight 
(P<0.001), waist circumference (P<0.001), BMI 
(P=0.001), SBP (P=0.004) FBS (P=0.001), TG 
(P=0.002), HDL (P=0.006) and number of MetS 
component (P<0.001). 
Moreover, in model 2, with adjusting for demo-
graphic variables, there was a significant associa-
tion between adiponectin and study groups 
(P<0.001), weight (P=0.004), waist circumference 
(P=0.008), BMI (P=0.001), FBS (P=0.001), TG 
(P=0.011), HDL (P=0.0042), number of MetS 
component (P<0.001), fat mass (P=0.01), fat free 
mass (P=0.01) and trunk fat (P=0.019). In multi-
ple linear regression analysis with backward 
method (model 3), there was a significant associa-
tion between adiponectin and gender (P=0.001), 
study groups (P<0.001) and SBP (P<0.042). With 
increasing one unit in SBP, the adiponectin was 
decrease by 0.017. 
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Table 5: Multiple linear regression for assessing association between adiponectin and related factors 
 
 Model 1a  Model 2 b  Model 3 c 
Variables β P-value  β P-value  β P-value 
Leptin(ng/ml) 0.027 0.228  -0.043 0.159    
Age(yr) -0.052 0.146       
Gender 2.2 0.001     2.073 0.001 
groups* -1.20 <0.001  -1.15 <0.001  -1.025 <0.001 
Weight (cm) -0.056 <0.001  -0.044 0.004    
Waist circumference 
(cm)  
-0.07 <0.001  -0.053 0.008    
BMI (Kg/m2) -0.169 0.001  -0.158 0.001    
SBP (mm-Hg) -0.057 0.004  -0.42 0.29  -0.017 0.042 
FBS (mg/dl) -0.029 0.001  -0.27 0.001    
TG (mg/l) -0.005 0.002  -0.004 0.011    
HDL-c (mg/dl) 0.077 0.006  0.057 0.042    
Number of MetS com-
ponent 
-0.678 <0.001  -0.637 <0.001    
Fat mass (%) -0.003 0.922  -0.106 0.01    
Fat free mass (%) 0.003 0.922  0.106 0.01    
Trunk fat (%) -0.035 0.293  -0.084 0.019    
a Crude model 
b Adjusted for demographic variables such as sex, age, marital status and educational level.  
cMultivariate backward linear regression model. 
*: study groups including; 1: normal weight metabolic healthy, 2: MHO, 3: MUO 
 
 
 
Fig. 1: ROC curves for adiponectin/leptin ratio, as 
predictors of MetS 
Criterion<0.726 
AUC=0.75 
95% CI=0.67-0.83 
SE=0.04 
P= 0.0001 
 
In addition, with increasing one unit in study 
groups (normal weight metabolic healthy groups 
in compare with MHO and MUO groups); the 
adiponectin was decrease by 1.025. The MetS 
group of study significantly has a low level of ad-
iponectin compared to other groups of study so 
that there is a decreasing trend of adiponectin 
level in study groups (Fig. 2). 
The results of linear regression showed that there 
is significant association between adiponec-
tin/leptin ratio with number of MetS compo-
nents (P<0.001) and study groups (P<0.001). 
With increasing one unit in number of MetS 
components, the adiponectin/leptin ratio was 
decreased by 0.366, so that there is a decreasing 
trend of adiponectin/leptin ratio according to 
number of MetS components and study groups 
(Figs. 2 and 3). Moreover, there is significant as-
sociation between leptin and number of MetS 
components (P=0.003) and study groups 
(P=0.001).  
With increasing one unit in number of MetS 
components, the leptin were increase by 1.87, so 
that there is an increasing trend of leptin accord-
ing to number of MetS components and study 
groups (Figs. 2 and 3). 
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Fig. 2: Trend of adiponectin, leptin and adiponectin/leptin ratio according to case and control groups 
 
 
 
Fig. 3: Trend of adiponectin, leptin and adiponectin/leptin ratio according to MetS components 
 
Discussion 
 
In the present study, we investigated the different 
levels of circulating adiponectin and leptin and 
adiponectin/leptin ratio among MHO and MUO 
patients as well as normal weight metabolic 
healthy subjects in Iranian adults. There were 
significant differences in the plasma adiponectin 
level between obese subjects with and without 
MetS (MHO and MUO groups). Serum adi-
ponectin was significantly lower in the MUO 
subjects than MHO as well as normal weight 
metabolic healthy subjects. This confirms the re-
sults of other studies (26, 27). In our study, the 
serum adiponectin level explained more specifi-
cally “healthy obese phenomenon” than leptin. 
Our data showed that the low levels of adiponec-
tin are associated with a considerable rise in FBS, 
TG, BP, WC, BMI, number of MetS compo-
nents, MetS development and declined in HDL-
c. These findings remain statistically significant 
after adjusting for leptin and body composition, 
indicating that adiponectin can partly explain the 
healthy obese phenomenon and protect against 
MetS development in MHO subjects. Higher ad-
iponectin levels were correlated with a favorable 
metabolic status and inflammatory profile (28).  
In the present study, serum, leptin in MUO pa-
tients was similar to that in the MHO group. 
Supporting this hypothesis originates from the 
studies that report no significant difference in the 
serum leptin levels between MHO and MUH 
subjects (28, 29). Furthermore, the obtained data 
is consistent with the results of other studies that 
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also showed that an elevated leptin level potenti-
ated insulin resistance and hypertension while 
adiponectin, on the contrary, possessed cardio-
protective effects (30). In addition present find-
ing is in agreement with some reports that 
demonstrated lower leptin/adiponectin ratio in 
MHO subjects (30). The adiponectin/leptin ratio 
was reported to be associated with insulin sensi-
tivity (31), and our study in agreement with pre-
vious document demonstrated that this ratio con-
tributed to the metabolic syndrome (28, 32). 
In current study, approximately reduced levels of 
adiponectin to 5.75 (µg/ml) and increased levels 
of leptin to 8.1 (ng/ml) (calculated from ROC 
curve) would be required to MetS development 
in our study participants. These cutoffs usually 
result in marked manifestation in the metabolic 
abnormalities associated with obesity and MetS 
formation. Therefore, the levels of leptin 
achieved in our MHO subjects (11.2 ng/ml) did 
not explain “healthy obese phenomenon”. In an-
other word, an elevated plasma leptin level alone 
does not determine metabolic status in obese 
subjects. All obese patients in our study, regard-
less of having MetS, generally had elevated level 
of leptin, fat mass and trunk fat as compared to 
normal weight metabolic healthy subjects. How-
ever, serum adiponectin levels in MHO as well as 
normal weight metabolic healthy subjects were 
higher than MUO patients. Although the leptin 
level itself powerfully predicts MetS, and meta-
bolic risk profile of obese subjects (33), our re-
sults suggest that adiponectin level above 5.75 
(µg/ml) is critical for achieving the healthy meta-
bolic status in MHO subjects. 
Abdominal obesity was accompanied by reduced 
adiponectin levels (34). The results of our study 
with regard to adiponectin in consistent with the 
previous evidence, adding that simultaneous 
presence of obesity and MetS, and not only obe-
sity, are required for the reduced adiponectin lev-
el. The difference in adiponectin levels observed 
between groups in the present study could ex-
plain the “healthy obese phenomenon”. We 
found that the magnitude of increase in serum 
adiponectin correlates with resistance to MetS 
development even among subjects with obesity. 
Even though the serum adiponectin level corre-
lated with body-mass index, the relationship be-
tween the serum adiponectin level and MetS was 
independent of obesity, and MHO subjects, as 
well as normal weight metabolic healthy individu-
al also exhibited adiponectin levels above 5.75 
(µg/ml). 
At present, there is no compelling evidence to 
suggest that the lower level of adiponectin con-
tributes to the onset of MetS in healthy obese 
individuals. However, maintenance of adiponec-
tin at high level may improve metabolic status 
and prevents the MetS formation in obese pa-
tients.  
Few tools exist to treat collectively the underlying 
pathophysiology of obese patients with MetS 
(35). Therefore, the ability to prediction the onset 
of the disease may constitute a new, clinically rel-
evant approach to implementing preventive life-
style interventions or prevention the MetS devel-
opment in high-risk patients who are overweight 
or obese. Because the reduction of serum adi-
ponectin level correlates with clinical signs and 
biochemical components of the MetS, measure-
ment of serum adiponectin could become a non-
invasive and accessible method of risk assess-
ment for MetS early-onset in healthy obese pa-
tients. 
 
Conclusion 
 
This study introduced adiponectin and leptin as 
indicator of MetS and obesity respectively. 
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